@gently I also read 2.5mg infusion dose is just as effective in trials as the 5mg dose! The 2.5 mg Dose in Research and Practice
Clinical Trials: Multiple studies have shown that a 2.5 mg dose of zoledronic acid can produce substantial and prolonged anti-resorptive effects on bone, with similar increases in bone mineral density (BMD) at the spine and hip compared to the 5 mg dose over a year. These studies suggest lower doses may offer similar efficacy with a potentially lower risk of side effects, such as the acute-phase reaction, which tends to be less frequent with lower doses.
Duration of Effect: A single 2.5 mg dose has been shown to prevent bone loss for at least 3 to 4 years, highlighting its potent and long-lasting action.
Specific Clinical Use: The 2.5 mg dose may be used in specific cases for patients with mild to moderate renal impairment, as the dosage may need to be adjusted to achieve a similar drug exposure as in a patient with normal renal function.
Cost-Effectiveness: In resource-limited health systems, the effectiveness of lower doses (like 2.5 mg or even 1 mg) has been explored as a potentially more cost-effective strategy to treat more patients at risk.